elotuzumab,bortezomib
abbvie,bms,takeda
['swog-1211', 'multiple myeloma', 'elotuzumab']
our is at #asco22 poster 477 sharing the results of a randomized phase ii trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (swog-1211). if you can t swing by, dr. usmani shares insights below. 
The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences